Healthcare Services

Fabry disease treatment market forecast (2026–2030)

April 21, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Fabry Disease Treatment Market Grow Between 2026 And 2030?

The fabry disease treatment market has shown robust growth over recent years. Its valuation is projected to expand from $2.27 billion in 2025 to $2.48 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.8%. This historical expansion can be ascribed to several factors including heightened awareness of rare genetic disorders, the successful approval of enzyme replacement therapies, the broader expansion of genetic testing, an increase in specialty hospitals, and augmented patient advocacy.

The Fabry disease treatment market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $3.34 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.8%. The projected growth during the forecast period is primarily driven by progress in gene therapy, the increasing adoption of personalized medicine, enhancements in newborn screening initiatives, the widening availability of oral therapies, and augmented funding for rare diseases. Key trends anticipated over the forecast period encompass a greater uptake of enzyme replacement therapy, an intensified focus on early genetic diagnosis, the expansion of oral chaperone therapies, an upsurge in research into gene therapy methodologies, and improved patient access to treatments for rare diseases.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/fabry-disease-treatment-global-market-report

Which Drivers Are Supporting The Fabry Disease Treatment Market Growth?

The rising occurrence of renal diseases is projected to boost the expansion of the fabry disease treatment market in the future. Renal diseases, also known as kidney diseases, encompass any conditions that hinder the proper functioning of the kidneys. The incidence of kidney diseases is on the rise due to genetic predispositions, lifestyle choices, environmental factors, and underlying health conditions. Fabry disease originates from the accumulation of globotriaosylceramide (Gb3) in kidney cells, leading to damage and dysfunction, which underscores the critical need for early detection and intervention to prevent kidney complications. For instance, in March 2023, the International Society of Nephrology (ISN), a Belgium-based professional society, reported that approximately 850 million people worldwide lived with chronic kidney disease (CKD), marking an increase compared to prior years. Consequently, the expanding prevalence of renal diseases is fueling the growth of the fabry disease treatment market.

Which Segment Categories Are Included In The Fabry Disease Treatment Market Segment Analysis?

The fabry disease treatment market covered in this report is segmented –

1) By Treatment: Substrate Reduction Therapy, Enzyme Replacement Therapy, Chaperone Treatment, Other Treatments

2) By Route Of Administration: Oral Route, Intravenous Route

3) By Disease Severity: Classic Fabry Disease, Late-Onset Fabry Disease

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Substrate Reduction Therapy: Migalastat Hydrochloride (Galafold), Other Substrate Reduction Therapies

2) By Enzyme Replacement Therapy: Agalsidase Beta (Fabrazyme), Agalsidase Alfa (Replagal), Other Enzyme Replacement Therapies

3) By Chaperone Treatment: Migalastat Hydrochloride (Galafold), Other Chaperone Therapies

4) By Other Treatments: Gene Therapy, Symptomatic Treatment

Which Trends Are Expected To Impact The Fabry Disease Treatment Market?

Leading companies in the Fabry disease treatment market are developing plant cell-based therapies with the aim of boosting therapeutic effectiveness, lowering treatment expenses, and improving patient outcomes through innovative and sustainable methods. Plant cell-based treatment for Fabry disease involves leveraging plant cells to produce enzymes that are deficient in individuals afflicted with the condition. These enzymes, derived from plants, serve as a therapeutic option to substitute the missing or defective enzymes within the body, striving to alleviate symptoms and enhance the health of patients suffering from Fabry disease. For instance, in May 2023, ELFABRIO gained approval, a joint effort by Chiesi Global Rare Diseases, an Italy-based pharmaceutical company, and Protalix BioTherapeutics Inc., an Israel-based pharmaceutical company. ELFABRIO offers an alternative treatment choice for individuals with Fabry disease. It functions as an enzyme replacement therapy (ERT) where the recombinant human a-Galactosidase-A enzyme is generated in plant-cell culture and subsequently modified with PEGylation to significantly extend its half-life. This treatment is designed to reduce administration frequency, improve convenience, and enhance the overall management of Fabry disease symptoms, thereby improving patient quality of life.

Who Are The Active Companies Shaping The Fabry Disease Treatment Market?

Major companies operating in the fabry disease treatment market are Sanofi S.A., Takeda Pharmaceutical Company Limited, Ultragenyx Pharmaceutical Inc., Sangamo Therapeutics Inc., Protalix BioTherapeutics, Avrobio Inc., Freeline Therapeutics Holdings PLC, M6P Therapeutics Inc., Yuhan Corporation, Orchard Therapeutics Ltd., Regenxbio Inc., Synlogic Inc., AceLink Therapeutics Inc., Greenovation Biotech GmbH, CANbridge Life Sciences Ltd., Sigilon Therapeutics Inc., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., Daiichi Sankyo Company Ltd., Audentes Therapeutics Inc., Genesis Therapeutics Inc., Idorsia Pharmaceuticals Ltd., JCR Pharmaceuticals Co Ltd., ISU Abxis Co Ltd.

Get The Full Fabry Disease Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/fabry-disease-treatment-global-market-report

Which Region Dominates The Fabry Disease Treatment Market By Market Share?

North America was the largest region in the fabry disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fabry disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Fabry Disease Treatment Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/fabry-disease-treatment-global-market-report

Browse Through More Reports Similar to the Global Fabry Disease Treatment Market 2026, By The Business Research Company

Lysosomal Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/lysosomal-disease-treatment-global-market-report

Plantar Fasciitis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/plantar-fasciitis-treatment-global-market-report

Gardner Syndrome Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/gardner-syndrome-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795